Print   



25 March 2009

Akers Biosciences, Inc.

(the 'Company')

Director/PMDR Shareholding

Akers Biosciences, Inc. a leading designer and manufacturer of rapid diagnostic screening and testing products, announces that Thomas A. Nicolette, the Company's President and Chief Executive Officer, has exercised warrants over 2,150,538 common shares at par value increasing his shareholding in the Company to 4,544,174 common shares, representing approximately 4.0% of the enlarged issued share capital. These warrants are the primary instrument in Thomas A. Nicolette's remuneration package.

Application has been made for the 2,150,538 common shares to be admitted to trading on AIM, such admission expected to take place on 30 March 2009.

Following Admission, the Company's enlarged issued share capital will comprise 113,495,634 common shares with voting rights. The Company does not hold any shares in treasury. This figure of 113,495,634 common shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FSA's Disclosure and Transparency Rules.

Enquiries: 

Thomas A. Nicolette

President and CEO

Tel. +1 856 848 8698 

Ben Simons or Eleanor Williamson

M:Communications

Tel. +44 (0)20 7153 1540 

Alasdair Younie

Arbuthnot Securities Limited

Tel. +44 (0)20 7012 2000

END

ENDRDSSEAFMLSUSEED